A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naive to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors. 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP) Genovese, M. C., Greenwald, M. W., Cho, C. S., Berman, A., Jin, L., Cameron, G., Xie, L., Braun, D., Banerjee, S., Warner, L. WILEY-BLACKWELL. 2011: S1017–S1017

View details for Web of Science ID 000297621503171